Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes

The transcription factor insulin promoter factor-1 (IPF-1) plays a central role in both the development of the pancreas and the regulation of insulin gene expression in the mature pancreatic beta cell. A dominant-negative frameshift mutation in the IPF-l gene was identified in a single family and sh...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 1999-11, Vol.104 (9), p.R33-R39
Main Authors: Macfarlane, W M, Frayling, T M, Ellard, S, Evans, J C, Allen, L I, Bulman, M P, Ayres, S, Shepherd, M, Clark, P, Millward, A, Demaine, A, Wilkin, T, Docherty, K, Hattersley, A T
Format: Article
Language:English
Subjects:
Adult
Aged
Blotting, Western
Cell Nucleus - metabolism
Cells, Cultured
Cytoplasm - metabolism
Diabetes Mellitus, Type 2 - genetics
DNA Mutational Analysis
Female
Genetic Predisposition to Disease
Glucose - metabolism
Homeodomain Proteins
Humans
Insulin - genetics
Male
Middle Aged
Mutation, Missense
Pedigree
Phenotype
Phosphorylation
Rapid Publication
Trans-Activators - genetics
Transcription, Genetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The transcription factor insulin promoter factor-1 (IPF-1) plays a central role in both the development of the pancreas and the regulation of insulin gene expression in the mature pancreatic beta cell. A dominant-negative frameshift mutation in the IPF-l gene was identified in a single family and shown to cause pancreatic agenesis when homozygous and maturity-onset diabetes of the young (MODY) when heterozygous. We studied the role of IPF-1 in Caucasian diabetic and nondiabetic subjects from the United Kingdom. Three novel IPF-1 missense mutations (C18R, D76N, and R197H) were identified in patients with type 2 diabetes. Functional analyses of these mutations demonstrated decreased binding activity to the human insulin gene promoter and reduced activation of the insulin gene in response to hyperglycemia in the human beta-cell line Nes2y. These mutations are present in 1% of the population and predisposed the subject to type 2 diabetes with a relative risk of 3.0. They were not highly penetrant MODY mutations, as there were nondiabetic mutation carriers 25-53 years of age. We conclude that mutations in the IPF-1 gene may predispose to type 2 diabetes and are a rare cause of MODY and pancreatic agenesis, with the phenotype depending upon the severity of the mutation.
ISSN:0021-9738
DOI:10.1172/jci7449